MedTrace Logo

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

NCT01899079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217

Last updated 2015-03-19

No results posted yet for this study

Summary

The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and actual treatments received for patients with early-stage breast cancer.

Conditions

Sponsors & Collaborators

  • Cedar Associates LLC

    collaborator OTHER

  • Illumina, Inc.

    collaborator INDUSTRY

  • Grupo Espanol de Investigacion del Cancer de Mama

    collaborator OTHER

  • Spanish Breast Cancer Research Group

    collaborator OTHER

  • Hospital General Universitario Gregorio Marañon

    collaborator OTHER

  • Vall d'Hebron Institute of Oncology

    collaborator OTHER

  • NanoString Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Miguel Martin, M.D., Ph.D. · Hospital General Universitario Gregorio Marañón

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-01-31
Completion
2014-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01899079 on ClinicalTrials.gov